- $31.36m
- $24.46m
- $7.53m
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma
Denmark's Evaxion Q1 net loss widens
Brief: Evaxion Promotes Birgitte Rønø To Joint Role Of Chief Scientific And Chief Operating Officer
Cancer drug developer Evaxion Biotech's FY25 net loss narrows on higher revenue
Brief: Evaxion Biotech Q4 Basic EPS USD -0.02
U.S. STOCKS ON THE MOVE-Centrus Energy, Generac Holdings
U.S. STOCKS ON THE MOVE-Centrus Energy, Oracle, Lamb Weston Holdings
Evaxion slides after Merck opts out of gonorrhea vaccine licensing agreement
U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Evaxion down after Merck opts out of gonorrhea vaccine licensing agreement
Brief: Evaxion A/S Prospectus Relates To Offer And Sale By Selling Shareholder000 Ordinary Shares
Brief: Evaxion Announces Positive Data For Lead Antigens In Cytomegalovirus (Cmv) Vaccine Program Evx-V1
Techbio firm Evaxion posts Q3 net income of $4.6 mln
Brief: Evaxion Appoints Dr Helen Tayton-Martin As New Chief Executive Officer
Brief: Evaxion Reports 75% Objective Response Rate In Phase 2 Trial With Ai-Designed Personalized Cancer Vaccine EVX-01
Evaxion soars on vaccine licensing deal for upto $592 million